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ORIGINAL ARTICLES—Laboratory science
Influence of topical human epidermal growth
factor on postkeratoplasty re-epithelialisation
MMM J Dellaert, T A Casey, S WiVen, J Gordon, P Johnson, A J M Geerards,
W J Rijneveld, L Remeijer, P G H Mulder, W H Beekhuis
Abstract
Aim—To test the eYcacy and safety of
recombinant human epidermal growth
factor (hEGF) on corneal re-
epithelialisation following penetrating
keratoplasty.
Methods—A prospective, randomised,
placebo controlled study was carried out
in which patients were matched for diag-
nosis and received either hEGF ophthal-
mic solution (30 µg/ml or 100 µg/ml) or
placebo in a double masked fashion.
Matched pairs of patients received donor
corneas from the same donor and were
operated by the same surgeon on the same
day. At the end of surgery all donor
epithelium was removed mechanically.
Patients were examined twice daily and
fluorescein stained photographs were
taken until the epithelium had closed. The
area of the defect was measured by
planimetry of the fluorescein stained
defect on the photographs.
Results—There were no significant diVer-
ences in re-epithelialisation of the donor
cornea between the placebo group and the
group treated with 30 µg/ml hEGF. Time
until complete closure was slightly longer
with 100 µg/ml hEGF compared with 30
µg/ml hEGF and with placebo. Mean heal-
ing rate of the epithelial defect with 100
µg/ml hEGF was significantly slower than
in the other groups.
Conclusion—No significant acceleration
of corneal re-epithelialisation was demon-
strated with the use of recombinant hEGF
after penetrating keratoplasty in humans.
(Br J Ophthalmol 1997;81:391–395)
Rapid corneal re-epithelialisation after pen-
etrating keratoplasty is crucial for graft sur-
vival. Epithelial defects increase the risk of
infection, vascularisation, thinning, perfora-
tion, and rejection of the graft. Any substances
which accelerate wound healing could reduce
these risks. In vitro and in vivo studies have
shown the important role of epidermal growth
factor (EGF) in growth regulation. EGF is a
naturally occurring monomeric polypeptide
and specific EGF receptors have been found to
be localised in the cell membranes of conjunc-
tival epithelium, corneal epithelium and en-
dothelium, posterior pigmented layer of the
iris, and the lens epithelium.1 Binding of EGF
to its transmembrane receptor activates an
intercellular cascade resulting in several meta-
bolic events, including stimulation of prolifera-
tion and diVerentiation of epidermal and other
cells.1 Previous studies of the influence of topi-
cally applied EGF on corneal wound healing
have been promising. In organ culture and ani-
mal in vivo studies, epidermal growth factor
isolated from mouse submaxillary glands
(mEGF) stimulated proliferation and DNA
synthesis of corneal epithelium and increased
the epithelial healing rate.2–6 Furthermore, ten-
sile strength of corneal wounds in rabbits was
increased by application of mEGF.7
Conflicting results of the eVect of mEGF on
corneal epithelium in humans have been
reported.While in 1979 Daniele et al 8 reported
an acceleration in the healing of non-
dystrophic diseases of human corneal epithe-
lium by mEGF, Kandarakis et al 9 could not
demonstrate any benefit of mEGF on epithelial
healing after penetrating keratoplasty. In the
mid 1980s biosynthetic human EGF (hEGF),
produced by yeast recombinant DNA tech-
niques, became available.10 Acceleration of
re-epithelialisation and a significant increase in
stromal wound strength was demonstrated in
in vivo studies on full thickness incisions in
rabbit and primate corneas treated with
recombinant hEGF.11–13
A prospective, randomised, double masked,
placebo controlled study was conducted to
evaluate the eVect of recombinant hEGF on
epithelial wound healing following penetrating
keratoplasty in humans.
Methods
The research followed the tenets of the Decla-
ration of Helsinki and the study protocol was
approved by the ethics committees of the indi-
vidual hospitals. Patients scheduled for pen-
etrating keratoplasty (with a diagnosis of kera-
toconus, pseudophakic bullous keratopathy,
and Fuchs’ dystrophy), who met all protocol
entry criteria and were willing to participate,
were enrolled in the study. Patients with a his-
tory of herpetic infections, glaucoma, or uveitis
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in the operative eye, no corneal sensation, a
Schirmer’s test less than 5 mm per 5 minutes,
and patients requiring the use of a bandage
lens or having a tarsorrhaphy immediately after
penetrating keratoplasty were excluded from
the study. Written informed consent was
obtained after explanation of the study pur-
pose, procedures, and patients’ responsibilities
to the potential participant. Patients were
matched in pairs. One patient of each pair was
randomly assigned to receive topical treatment
with hEGF (either 30 µg/ml or 100 µg/ml) and
the other patient to receive placebo. Neither
the investigator nor the patient was aware of
the treatment group assignment until after
completion of the study.
The study medication was provided by Chi-
ron Vision in sealed packages assigned to
matched pairs of patients. Human epidermal
growth factor ophthalmic solution (hEGF),
derived from yeast cultures using recombinant
DNA technology, was used as a unit dose,
unpreserved solution at a concentration of 30
µg/ml or 100 µg/ml in phosphate buVered
saline with stabilisers. Placebo consisted of the
same vehicle solution excluding the hEGF, and
was provided as a unit dose, unpreserved solu-
tion, identical in appearance to the hEGF solu-
tion. On day 0 of the study each patient had
penetrating keratoplasty performed using
standard microsurgical techniques. Each pair
of matched patients was operated on the same
day, by the same surgeon, and received mate
donor corneas; these corneas were preserved in
tissue culture medium (MEM).14 Identical
suture technique, graft size, and recipient bed
size were used for both corneas of the pair. For
combined cataract surgery and intraocular lens
implantation matching was also done. After the
graft had been sutured, all donor epithelium
was removed mechanically by microsponge
wiping. Fluorescein was instilled to verify com-
plete epithelial removal on the surface of the
graft. At the end of the procedure antibiotics
(gentamicin) and steroid (betamethasone)
were injected subconjunctivally and two drops
of the study medication were administered.
The eye was then pressure patched until the
next morning.
Postoperative medication consisted of study
medication administered four times a day until
the epithelial defect was closed; chlorampheni-
col 0.5% eyedrops three times a day; and pred-
nisolone 0.5% eyedrops six times a day, all
without preservatives. Prednisolone and chlo-
ramphenicol drops were administered 2 hours
after instillation of the study medication.
Patients were examined twice daily from day
1 until complete epithelial closure. The ante-
rior segment was inspected for signs of inflam-
mation, signs of conjunctival ischaemia, size of
the epithelial defect, and superficial punctate
keratopathy. A colour photograph of the
cornea was taken 5 seconds after instillation of
fluorescein. A slit-lamp connected photo-
camera was used with a magnification of 75 ×
(12.5 ×–6 ×) and Kodak PRD 135-36 200 ASA
colour films. Photographs were processed in an
IMAGEnet system (Topcon, Itabashiku, Tokyo,
Japan). From the converted photograph on the
screen the area of the defect could be estimated
by planimetry. Paired Student’s t test was used
to compare mean time to complete closure of
the defect between groups. To estimate the
percentage decrease in the area of the defect, a
random coeYcients model (rmANOVA) with
time was used, after expressing the area as per-
centage of baseline and taking the logarithm of
this percentage. Follow up examinations were
performed 1 week, 1 month, 6 months, 1 year
and, if possible, 2 years postoperatively. Best
corrected visual acuity was measured and
slit-lamp examination of the anterior segment
was performed at each examination. On days 7
and 28 central corneal thickness was estimated
by ultrasonic pachymetry and intraocular pres-
sure was measured.
Results
Thirty six patients entered the study, nine
receiving 100 µg/ml hEGF, nine receiving 30
µg/ml hEGF, and each paired with a patient
receiving placebo. In all but one case, matched
pairs had the same indication for penetrating
keratoplasty (Table 1). There were no impor-
tant demographic diVerences between the
treated and the control groups (Table 2). Data
relevant to the surgical procedure are shown in
Table 3. Twenty five patients underwent
penetrating keratoplasty only. Eight patients
had penetrating keratoplasty combined with
extracapsular cataract extraction and implanta-
tion of a posterior chamber lens in the capsular
Table 1 Indications for penetrating keratoplasty
hEGF
(100 µg/ml) Placebo
hEGF
(30 µg/ml) Placebo
Keratoconus 4 4 6 5
Pseudophakic BKP 1 1 1 1
Fuchs’ dystrophy 4 4 2 3
Total 9 9 9 9
hEGF = human epidermal growth factor; BKP = bullous keratopathy.
Table 2 Demographic variables of all 36 patients under study
hEGF
(100 µg/ml)
(n=9)
Placebo
(n=9)
hEGF
(30 µg/ml)
(n=9)
Placebo
(n=9)
Mean age (SD) (years) 55.96 (19.94) 52.14 (19.32) 44.59 (22.97) 42.36 (26.20)
Sex (M/F) 4/5 6/3 3/6 3/6
Race
White 7 9 9 6
Asian 1 0 0 2
Hispanic 1 0 0 0
Other 0 0 0 1
Table 3 Summary of surgical data of all 36 study patients underdoing penetrating
keratoplasty
hEGF
(100 µg/ml)
(n=9)
Placebo
(n=9)
hEGF
(30 µg/ml)
(n=9)
Placebo
(n=9)
Donor size (mm) (mean
(SD)) 7.75 (0.25) 7.75 (0.25) 7.67 (0.25) 7.78 (0.26)
Bed size (mm) (mean
(SD)) 7.44 (0.17) 7.44 (0.17) 7.93 (0.22) 7.50 (0.25)
ECCE 3 3 1 1
IOL removed 1 1 0 1
IOL implant 4 4 1 2
PC 3 3 1 1
Iris 1 1 0 1
Vitrectomy 1 1 2 1
Complications 1 0 0 0
ECCE = extracapsular cataract extraction; IOL = intraocular lens; PC = posterior chamber lens;
Iris = iris fixated lobster claw lens.
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bag. Three of the patients with pseudophakic
bullous keratopathy underwent removal of the
intraocular lens followed by implantation of an
iris fixated intraocular lens (Worst Lobster
Claw lens, Ophtec, Groningen, the Nether-
lands). In three of the latter cases anterior vit-
rectomy was performed. The one intraopera-
tive complication was a rupture of the posterior
lens capsule during extracapsular cataract
extraction.
The primary eYcacy variable was time to
complete healing of the epithelial defect.
Figures 1 and 2 show the mean size of the
defect, estimated by planimetry at each
examination until complete closure, for the
group receiving 100 µg/ml hEGF and the
placebo group and the group receiving 30
µg/ml hEGF and the placebo group. Size of the
baseline defect (size of defect at day 0) was the
size of the recipient bed. There were no signifi-
cant diVerences between treated and control
patients in mean time until complete closure of
the epithelial defect. Healing time was slightly
longer in the 100 µg/ml hEGF group compared
with the placebo group, mean 5.1 (SD 4.3)
days versus 3.4 (1.0) days (p = 0.232), and also
longer than in the 30 µg/ml hEGF group and
its control group, 3.9 (3.1) days versus 3.5
(1.7) days (p = 0.718). Mean percentage
decrease of the defect area per 12 hours was
29% in the 100 µg/ml hEGF group compared
with 44% in its placebo group (p <0.0005). In
the 30 µg/ml hEGF group the percentage
decrease was 52%/12 hours compared with
35%/12 hours in its placebo group
(p = 0.147).
Within the first postoperative week a tran-
sient fibrinous reaction was seen in seven
eyes—three in the group of patients treated
with 100 µg/ml hEGF, one in the group treated
with 30 µg/ml hEGF, and three in the placebo
control group. All aVected eyes had other sur-
gical procedures performed in addition to the
penetrating keratoplasty. No correlation be-
tween the fibrinous reaction and the use of
either the 100 µg/ml or the 30 µg/ml hEGF
could be demonstrated. In two eyes an inflam-
matory reaction around a few of the nylon
sutures on the recipient side was noted; one eye
was treated with placebo and the other with 30
µg/ml hEGF. During the first postoperative
days all eyes showed conjunctival hyperaemia.
There was no conjunctival oedema or capillary
closure which could have been associated with
the subconjunctival injection of gentamicin at
the end of surgery.15 Mean pachymetry meas-
urements at days 7 and 28 following kerato-
plasty are shown in Table 4. The nine patients
receiving 100 µg/ml hEGF therapy showed a
significantly thicker cornea compared with the
placebo control group at day 7. There were no
significant diVerences in intraocular pressure
between the groups at any time.
Follow up results at 6 months, 1 year, and 2
years after surgery are shown in Table 5. Com-
plications were encountered in six cases. Three
patients needed revision of their sutures—one
in the placebo group, one in the group treated
with 30 µg/ml hEGF, and one in the group
treated with 100 µg/ml hEGF. Overall, more
suture related problems (loose sutures, infil-
trates at suture sites) were encountered in the
total population of study patients than are gen-
erally seen in our routine keratoplasty cases.
One patient receiving placebo treatment re-
quired a second penetrating keratoplasty in the
operated eye because of nebulae formation in
the graft, caused by a stromal allograft
reaction. One other patient in the placebo
group did have a transient endothelial rejection
reaction which resolved with steroid therapy. A
true rejection reaction requiring repeat pen-
etrating keratoplasty was seen at 19 months
postkeratoplasty in one patient treated with
100 µg/ml hEGF. All other eyes in both the
hEGF treated groups and the placebo groups
did comparably well.
Figure 1 Change in area of epithelial defect with time after penetrating keratoplasty. Size
of defect at day 0 was the size of the recipient bed. Each point represents the mean (SD);
area of epithelial defect was estimated by planimetry.
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Figure 2 Change in area of epithelial defect with time after penetrating keratoplasty. Size
of defect at day 0 was the size of the recipient bed. Each point represents the mean (SD);
area of epithelial defect was estimated by planimetry.
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Table 4 Corneal thickness (µm) on days 7 and 28 following penetrating keratoplasty
(mean (SD))
hEGF
(100 µg/ml) Placebo p Value*
hEGF
(30 µg/ml) Placebo p Value*
Day 7 693 (74) 612 (62) 0.002 655 (50) 663 (75) 0.709
Day 28 523 (37) 536 (38) 0.268 533 (50) 547 (58) 0.609
*Paired Student’s t test.
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Discussion
Epidermal growth factor has been demon-
strated by radioimmunoassay to be present in
human tears.16 17 Compared with the tear film
of healthy control eyes, the concentration of
EGF in the tear film of eyes with ocular surface
disease is significantly lower.18 In such cases,
including penetrating keratoplasty, an increase
in EGF concentration to enhance epithelial
recovery would seem desirable. In this study
we tested the eYcacy and safety of hEGF eye-
drops on re-epithelialisation of the denuded
human cornea after penetrating keratoplasty.
The eVect of two diVerent dosages of hEGF,
30 µg/ml and 100 µg/ml, were compared with
the eVect of placebo, in a double masked fash-
ion. This is, to our knowledge, the first report
on the use of recombinant hEGF in humans.
There were no significant diVerences in
re-epithelialisation of the donor cornea after
penetrating keratoplasty between the group
treated with 30 µg/ml hEGF and placebo con-
trol group. Mean healing time to closure of the
defect with topical application of 100 µg/ml
hEGF was actually slightly longer compared
with the other three groups. This is reflected in
the significantly lower percentage decrease of
the defect area per 12 hours after treatment
with 100 µg/ml hEGF. This could be explained
by down regulation of the receptor sites.19
Binding of hEGF to its plasma membrane
receptor is followed by internalisation and deg-
radation of the EGF–receptor complex, with-
out concomitant production of new receptors.
If an abundance or excess of EGF is presented
to the receptors all receptor sites will be occu-
pied and for some time no receptor sites will be
available.11
A high incidence of suture related problems
was noted in this study, both in the group
treated with hEGF and in the placebo control
group. This may be related to the mechanical
removal of the corneal epithelium at the end of
the surgery, a procedure we do not normally
perform. The transient increase in corneal
thickness measured on day 7 of the study in the
100 µg/ml hEGF group might reflect hyperpla-
sia and hypertrophy of the epithelium in EGF
treated eyes, as reported previously by other
investigators.2 3 20 However, this does not fit
with the longer mean time to closure of the
defect, since a shorter healing time would be
expected with hyperplasia and hypertrophy.
It may be that dysregulation of re-
epithelialisation is induced by a relative over-
load of hEGF in a concentration of 100 µg/ml.
Otherwise, hEGF eyedrops were well tolerated
and no signs of toxicity could be observed.
It is known that both steroids and antibiotics
can retard corneal wound healing,7 20–22 but all
patients received the same concomitant topical
medication in the operated eye and there
should have been no diVerence between the
groups in this respect.
Although increase in corneal wound
strength by hEGF has been demonstrated in
vivo in animals, it has not been determined in
this study because the operated eye has to be
sacrificed to estimate stromal wound
strength.11 13
Patients with essentially normal corneal sur-
face, presumably with normal EGF in the tear
film, do not benefit from supplementation of
hEGF in the postoperative phase for epithelial
healing rate. This study has not addressed the
possible advantage of hEGF supplementation
to patients undergoing corneal grafting with
abnormal ocular surface, sensibility defects, or
tear insuYciencies.
During the course of our study Sheardown et
al23 reported the optimal concentration of
hEGF to accelerate wound healing to be 50
µg/ml and also found that an increase in expo-
sure time reduced healing time. Taking these
findings into account the doses we used may
have been too low or too high and the exposure
time too short. A gel at a concentration of 50
µg/ml with controlled release of hEGF might
be a more successful adjuvant than eyedrops in
slowly healing corneas after penetrating kerato-
plasty.
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